The FDA sent
letters over the past two weeks to nearly a dozen companies, including
Washington-state based Canna Companion, which markets a supplement
infused with hemp to dog and cat owners.
"This product is an unapproved new animal drug and your
marketing of it violates the FD&C Act," the letter reads. The act
gives the FDA authority to oversee safety and benefit claims of food,
drugs and cosmetics.
Warning letters have also been sent to Seattle-based Canna-Pet,
LLC, which makes pet treats and supplements infused with CBD, an active
cannabinoid, and to California-based Hemp Oil Care, which sells
cannabis-infused "products for therapeutic healthcare purposes" marketed
to humans.
"The reason they got warning letters is not what is or isn't in the
product," said FDA spokesman Jeff Ventura. "It's because they made
therapeutic claims."
The letters require each company to remove claims on its website,
packaging and marketing material that the products can improve health or
prevent disease and illness.
The FDA, which says it supports research into cannabis,
said scientists tested all the cannabis-laced products to ensure they
did not pose a risk to public safety.
In some cases, products that claimed to owe their benefits
to cannabis contained less of the compound than advertised or none at
all, Ventura said.
No comments:
Post a Comment